Epratuzumab Tesirine

Products from BPS Bioscience require a minimum order value above 400€

Background: CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It acts as an inhibitory co-receptor of the B-cell receptor to control the B-cell immune response. In 2017 the FDA approved Besponsa, an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.

Description: Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG32491.

Storage Stability: Room Temperature

Target: CD22

Uniprot: P20273

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: Not applicable (BSL-1)

References: 1. Francesca Zammarchi, et al., 2024 Mol Cancer Ther. 23(4):520-531.

• SKU: BPS82919-2
• Manufacturer: BPS Bioscience
• Manufacturer SKU: 82919-2
• Package Unit: 5 mg
• Quantity Unit: STK
• Clonality: Monoclonal